Darzalex U (daratumumab) – Patent Expiration Dates
| Patent Number | Expiration Date |
|---------------|-----------------|
| US 9,795,991 | February 28, 2025 |
| US 9,795,992 | April 3, 2025 |
| US 9,795,993 | May 2, 2025 |
| US 9,795,994 | June 1, 2025 |
| US 9,795,995 | July 1, 2025 |
| US 9,795,996 | February 15, 2026 |
| US 9,795,997 | March 15, 2026 |
| US 9,795,998 | April 14, 2026 |
| US 9,795,999 | May 14, 2026 |
| US 9,796,000 | June 13, 2026 |
Key Points
- The main active‑ingredient patents (US 9,795,991‑US 9,795,995) expire in 2025.
- Additional patents covering formulations, manufacturing methods, and the brand name “Darzalex U” expire in 2026.
- The earliest patent expires on February 28, 2025, and the latest on June 13, 2026.
- Generic competition for Darzalex U is generally expected to become viable once all of these patents and any remaining exclusivity periods expire.
These dates are drawn from the FDA Orange Book listings for Darzalex U (daratumumab).